anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Although OCTN2 is fairly well studied in its relationship with SCD, little is known about the carrier frequency of disease-causing alleles of OCTN2, or of more common functional polymorphisms in this gene. To address these issues, we screened for genetic variants in the OCTN2 coding region by direct sequencing of the exons and flanking intronic region of OCTN2 in a large sample (n = 276) of ethnically diverse subjects. In addition, we established lymphoblastoid cell lines from subjects homozygous for either allele of the previously identified promoter region variant, -207G\>C. We found eight amino acid sequence variants of OCTN2, of which three (Phe17Leu, Leu144Phe, and Pro549Ser) were polymorphic in at least one ethnic group. When assayed for functional activity by expression in human embryonic kidney 293 cells, using as probes both the endogenous substrate (l-carnitine) and the organic cation tetraethylammonium, three variants showed functional differences from the reference OCTN2 (Phe17Leu, Tyr449Asp, Val481Phe; p \< 0.05). Further studies of the Phe17Leu polymorphism showed a reduced V(max) for l-carnitine transport to approximately 50% of the reference OCTN2. Confocal microscopy studies using an OCTN2-GFP fusion protein showed that Phe17Leu had distinct subcellular localization from the reference OCTN2, with diffuse cytoplasmic retention of Phe17Leu, in contrast to reference OCTN2, which localized specifically to the plasma membrane. Lymphoblasts from subjects homozygous for the -207G allele showed increased l-carnitine transport compared with the -207C/C homozygotes (p \< 0.05). This study suggests that although loss-of-function mutations in OCTN2 are likely to be rare, common variants of OCTN2 found in healthy populations may contribute to variation in the disposition of carnitine and some clinically used drugs.
Women who were deemed eligible for the study by the provider gave informed consent. They took 200 mg of mifepristone orally at the study clinic. In 24-44 hours, they returned to the clinic for induction with misoprostol. They were admitted as inpatients at the clinic and took 400 mcg of buccal misoprostol every 3 hours until the fetus and placenta were expelled. If there was no full expulsion after 10 doses of misoprostol, the provider used their discretion to determine the appropriate clinical course of action. After responding to questions about their experience with the procedure, women were discharged from the study.
Posttest: The swaddling method will be applied to the newborn after the first saliva sample is taken. A second saliva sample will be taken 30 minutes after swaddling to measure cortisol level. Immediately after the saliva sample is taken in posttest group, the stress level determined by using the "neonatal stress scale", vital signs, saliva sample collection time will be recorded on the chart.
Float-REST therapy uses sensory deprivation tanks that consist of a very large warm water enclosure with a high concentration of Epsom salt to create a completely buoyant environment. This, along with a combination of temperature that is kept equal to skin temperature (94 degrees), allows the participant to eliminate the gravitational effects on the body, and along with lack of sound and low to no light (depending on comfort) allows the brain and body to completely relax for augmented physical and mental recovery. The room will contain an intercom that allows participants to communicate with study personnel in the event the participant needs assistance. Participants will undergo 60 minute sessions twice a week for 3 weeks.
The invention relates to magnet-therapy pasties for preventing breast diseases and usage thereof. Each of the magnet-therapy pasties comprises, from bottom to top, a coated breast-brace base, a paste layer, magnet therapy pieces and release paper; a through hole, corresponding to the nipple in size, is formed in the center of each of the magnet-therapy pasties for preventing breast diseases. The coated breast-brace base is made of medical macromolecule coated fiber fabric and provided with a plurality of nano-pores. The paste layer comprises traditional Chinese medicine components and polyacrylate pressure sensitive adhesive. The magnet-therapy pasties for preventing breast diseases are safe, free of peculiar smell, convenient to use, dry and breathable, and have effect of improving microcirculation, promoting blood circulation to remove blood stasis, relieving swelling and pain and preventing mastitis. As the magnet-therapy pasties are of ergonomic design, the magnet-therapy pasties are high in comfortableness in use and capable of matching different breast size and shape; with scientific compatibility of traditional Chinese medicines and reasonable content of the different components, the magnet-therapy pasties are easy to produce, are safe and convenient to use and remarkable in treatment effect.
The invention relates to a skin-tightening mixture comprising: between 10 and 80 wt. % of a polysaccharide, preferably an alginate, having a molecular weight of less than 600,000 Daltons, advantageously less than 400,000 Daltons and, better still, less than 200,000 Daltons; between 15 and 75 wt. % of a polyhydroxylated agent selected from among sugars and the derivatives thereof, in particular sugar ethers and esters, preferably sorbitol; between 3 and 15 wt. % of polyvinyl alcohol or polyvinylpyrrolidone; between 0 and 25 wt. % of cellulose or a cellulose derivative, such as carboxymethylcellulose or hydroxymethylcellulose.  The invention also relates to cosmetic compositions containing said mixture.  The aforementioned cosmetic compositions can be used for the progressive mechanical smoothing of the surface of the skin, said compositions being extremely comfortable to use and providing a good base for applying make-up.
Using octoploid somatic hybrids with excessive C genome sets, AABBCCCC, a diverse allohexaploid, AABBCC, was produced by C genome reduction through subsequent crossing with various AABB cultivars. Even when somatic hybrids are produced, the plants that are produced are rarely in themselves an innovative crop. In this study, we used somatic hybrids of Brassica juncea (AABB) and B. oleracea (CC) as model cases for the genetic diversification of the somatic hybrids. One cell of 'Akaoba Takana' (B. juncea) and two cells of 'Snow Crown' (B. oleracea) were fused to create several somatic hybrids with excessive C genomes, AABBCCCC. Using AABBCCCC somatic hybrids as mother plants and crossing with 'Akaoba Takana', the AABBCC progenies were generated. When these AABBCC plants were self-fertilized, and flow cytometric (FCM) analysis was performed on the next generations, differences in the relative amount of genome size variation were observed, depending on the different AABBCCCC parents used for AABBCC creation. Further self-progeny was obtained for AABBCC plants with a theoretical allohexaploid DNA index by FCM. However, as the DNA indices of the progeny populations varied between plants used and aneuploid individuals still occurred in the progeny populations, it was difficult to say that the allohexaploid genome was fully stabilized. Next, to obtain genetic diversification of the allohexaploid, different cultivars of B. juncea were crossed with AABBCCCC, resulting in diverse AABBCC plants. Genetic diversity can be further expanded by crossbreeding plants with different AABBCC genome sets. Although genetic stability is necessary to ensure in the later generations, the results obtained in this study show that the use of somatic hybrids with excess genomes is an effective strategy for creating innovative crops.
The rate of unintended pregnancy among opioid-dependent women is extremely high: nearly 9 of every 10 pregnant opioid-dependent women report that the current pregnancy was unintended, a rate 2-3 times that of the general population. Despite these dire statistics, there is a dearth of scientific knowledge about contraceptive use in this population and about how to promote use of more effective contraceptives (e.g., birth control pills, IUDs, implants).

The aim of this Stage I Behavioral and Integrative Treatment Development Program application is to develop and pilot test a novel contraceptive management program to increase use of more effective contraceptives among OM women. OM women (N=100) at risk for unintended pregnancy will be randomly assigned to a 6-month contraceptive management program or to usual care. The contraceptive management program will consist of two components: (1) the World Health Organization's contraception protocol and (2) reinforced follow-up visits. At their first visit, participants assigned to the contraceptive management program will complete the WHO's contraception protocol, which consists of assistance choosing a contraceptive method, structured educational counseling about their chosen method, a free supply of this method, and the option of initiating this method immediately. Subsequently, contraceptive management program participants will earn voucher-based incentives to reinforce attendance at follow-up visits where they will receive support to manage side effects and problem-solve compliance problems, refills of their chosen method, and assistance switching methods when indicated. At each visit, contraceptive management program participants will also be counseled about the risks of sexually transmitted infections (STIs), including HIV/AIDS, the need for dual protection (i.e., protection from both pregnancy and STIs), and provided with a supply of condoms. Participants assigned to the usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services. Contraceptive use by all participants will be evaluated at assessments scheduled 1, 3, and 6 months after trial intake. The impact of prescription contraceptive use on condom use will also be assessed. It is hypothesized that the contraceptive management program will increase effective contraceptive use without decreasing condom use.

The proposed project will be the seminal study of an intervention to increase more effective contraceptive use in OM women and the first step towards our overarching goal of developing an efficacious, empirically based contraceptive management program that can be disseminated to drug treatment facilities throughout the country. The proposed research also holds significant potential for impacting public health in general, as development of efficacious programs will help reduce the vast economic and societal costs associated with unintended pregnancy among drug-dependent and non-drug-dependent women alike.
Participants will be guided through a 45 minutes exercise program, set up as a group exercise class, with program modifications being made for each individual participant. In order to meet the requisite number of participants there will be approximately 4 cohorts of 10 participants. Immediately after the exercise class participants will attend a 30-minute educational session. The educational sessions will cover bone health principles, nutrition for bone health, osteoporosis practice guidelines, ways to self-monitor balance and lower extremity strength, impacts of physical activity, home hazard detection, hazards at work and in the community, postural effects on bone loading and fracture risk, and integrating physical activity in daily life. Nutritional education will emphasize the importance of calcium and vitamin D, sources of both diary and dairy free calcium, vitamin D supplements, the importance of protein, and meat and meat-free sources of protein.
In the first part of the study safety and clinical efficacy of ALK Alutard Birch or 5-grass have been evaluated in a RCT with 50 patients. Active patients recieve 3 injections with 1000 SQ-U ALK Alutard or 5-grasses in a lymph node in the groin. Dose interval 4 weeks. This part of the study is completed and published (PMID: 23374268)

In the second part of the study 60 patients participates in a RCT with intralymphatic injections with both ALK Alutard Birch AND ALK Alutard 5-grasses. The injections are given intralymphatically with one allergen in each groin with 30 minutes observation between injections. Dose and dose interval are the same as in the first part of the study; the active group recieves 1000 SQ-U ALK Alutard Birch in right groin and 1000 SQ-U 5-grasses in left groin. The injections are given 3 times with 4 weeks interval. Enrollment and treatment is completed and the results will be evaluated in the autumn 2015.
Antimitotic extracts, having strong activity and low toxicity, are obtd. from the tissue or the medium obtd. by in vitro cultivation of new strains of Catharanthus roseus G. Don. These strains are produced by creation of a large diversified population of such strains and selection of active strains from this population. The two retained strains have the following characteristics:- a) each strain comprises a collection of calluses forming a primary callus clone, derived from a fragment of stem of a sterile shoot of a heterogeneous, ornamental variety, each strain coming from different seeds; b) each strain is cultivated in a medium contg. mineral macro-elements (Murashige and Skoog solution 100 ml/l), mineral micro-elements (Heller solution 1ml/l), vitamin B1 complex (2 ml/l), ferric chloride hexahydrate (1mg/l), 1-naphthyl-acetic acid (1mg/l), 6-(furfurylamino)-purine (1mg/l), glucose (30mg/l) and gelose (7g/l); or opt. without gelose c) each strain is cultivated at 22 deg.C, under 2500 lux illumination for 16 hrs./day and the period of cultivation before seeding fresh medium is five weeks; d) the strains have a granular morphologic appearance, and very friable and show total absence of organogenesis. The two retained strains are CR-1, which has clear green pigmentation and a growth level of the order of 6 times the size of the initial implant per cultivation cycle; CR-2 has green pigmentation and a growth level of 12 times that of the initial implant per cultivation cycle. Antimitotic which retards growth of L1210 leukaemia cells and has low toxicity. The I.V. LDO in Charles River 20g mice is greater than 300 mg/kg. Activity tests compare CR-1 extract with vinblastine on human fibroblasts and show the superior effect of the CR-1 extract.
Patients will receive weekly paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 21-day treatment cycle. Treatment will continue until disease progression, unacceptable toxicity, death or discontinuation for any other reason.
The current disclosure reveals a complex regulatory pattern between miR-31 and AR, indicating that miR-31 plays a key role in prostate cancer development and progression. Another aspect of the current disclosure shows that miR-31 directly targets and destabilizes AR mRNA through interaction with the AR mRNA coding sequence showing that miR-31, or a fragment thereof has the ability to act as a novel therapeutic agent in treating cancer. The current disclosure also shows that AR indirectly represses miR-31 expression by binding to the miR-31 promoter region and modulating methyltransferase activity. Another aspect of the current disclosure shows that miR-31 indirectly modulates AR activity by modulating regulators of cell cycle progression. The disclosure further provides an isolated nucleic acid that modulates the activity of the androgen receptor in a cell. The disclosure further provides a method of treating a prostate cancer in a subject, by administering to the subject an effective amount of an agent that modulates the activity or levels of miR-31.
A method of manufacturing an ulcer treatment is disclosed. Ulcer symptoms, including stomach pain, bloating, heartburn, nausea, and more, can be highly intrusive on a patient's life. In order to create a treatment, several acorns, particularly acorns from Quercus brantii, commonly known as a Persian Oak tree, are acquired. These acorns are sorted and subsequently washed in water to free them of any dirt or contaminants. The acorns are then crushed to separate the acorn nuts from their corresponding acorn shells. The shells are discarded, and the acorn nuts are washed in room-temperature water again to remove any nut impurities. The acorn nuts are then roasted in an oven for several minutes to remove the nut skin from the nut. The nut skin and the nut body are collected and pulverized separately to create an ulcer-treating powder. The ulcer-treating powder may subsequently be mixed into a solvent and ingested by the ulcer patient to treat the patient's ulcers and ulcer symptoms.
Macular corneal dystrophy (MCD) is a progressive, bilateral stromal dystrophic disease that arises from mutations in carbohydrate sulfotransferase 6 (CHST6). Corneal transplantation is the ultimate therapeutic solution for MCD patients. Unfortunately, postoperative recurrence remains a significant challenge. We conducted a retrospective review of a clinical cohort comprising 102 MCD patients with 124 eyes that underwent either penetrating keratoplasty (PKP) or deep anterior lamellar keratoplasty (DALK). Our results revealed that the recurrence rate was nearly three times higher in the DALK group (39.13%, 9/23 eyes) compared with the PKP group (10.89%, 11/101 eyes), suggesting that surgical replacement of the corneal endothelium for treating MCD is advisable to prevent postoperative recurrence. Our experimental data confirmed the robust mRNA and protein expression of CHST6 in human corneal endothelium and the rodent homolog CHST5 in mouse endothelium. Selective knockdown of wild-type Chst5 in mouse corneal endothelium (ACsiChst5), but not in the corneal stroma, induced experimental MCD with similar extracellular matrix synthesis impairments and corneal thinning as observed in MCD patients. Mice carrying Chst5 point mutation also recapitulated clinical phenotypes of MCD, along with corneal endothelial abnormalities. Intracameral injection of wild-type Chst5 rescued the corneal impairments in ACsiChst5 mice and retarded the disease progression in Chst5 mutant mice. Overall, our study provides new mechanistic insights and therapeutic approaches for MCD treatment by high-lighting the role of corneal endothelium in MCD development.
The utility model relates to an external-use emplastrum for medical treatment and health care. A macromolecule gel layer 2 with medicine is arranged on the emplastrum. A soft plastic coating layer 1 is adhered to the upper surface of the macromolecule gel layer. An isolation layer 3 arranged on a non-woven fabric base layer 4 is adhered to the lower surface of the macromolecule gel layer. The isolation layer is made of a poromeric medical polymer sizing agent and is coated on the nonwoven fabric base layer. The utility model has the advantages of easy adherence, and comfortable utilization, and has no skin pull, no fine hair damage, no skin and clothing pollution, etc; in addition, the utility model is easy to tear off.
Epilepsy affects about 1% of the population, with roughly 30% of patients with epilepsy eventually developing drug-resistant epilepsy (DRE). Increasingly, surgery is pursued for DRE, yielding seizure freedom rates of 50-70%. However, accurate deduction of the epileptogenic zone (EZ) for surgical planning can be difficult in pediatric DRE, especially in those cases of multifocal seizures, as is often seen in Tuberous Sclerosis Complex (TSC), for example. Patients with multifocal epilepsy typically require a period of pre-surgical invasive EEG monitoring to record spontaneous seizures, the gold standard for EZ deduction. Unfortunately, the invasive monitoring process may be lengthy, costly and even fail to reveal a dominant EZ.

Electrical stimulation of induced seizures (ESIS) using stereo EEG (sEEG) has been shown to be a safe and valid adjunct for EZ delineation in adults with DRE. ESIS can be implemented within 1-2 days of electrode implantation, while the patient would otherwise be passively awaiting spontaneous seizures. ESIS typically induces habitual seizures with few side effects, and there is no data to suggest that ESIS inhibits spontaneous seizures or prolongs the otherwise clinically-indicated hospital stay. Crucially, published data show that induced seizures provide information about the EZ that is both convergent with and unique from that provided by spontaneous seizures. Despite these promising reports, ESIS is not widely integrated into pediatric DRE evaluation.

The overall objective is to improve methods of EZ identification in pediatric DRE patients with complex EZs, thereby increasing the likelihood of surgical candidacy for patients and ultimately improving surgical outcomes. In this protocol, investigators hypothesize that electrical stimulation of induced seizures (ESIS) is an effective adjunct for EZ delineation in children with DRE. To test this, the study will enroll n=86 patients with DRE undergoing sEEG evaluation aged 1-30 years. Based on the CCHMC epilepsy surgery program throughput, it is anticipated that this will include approximately n=36 patients with TSC and n=50 without TSC, which will provide the opportunity to compare the utility of this technique between patients with and without TSC. Patients will undergo ESIS using published Cincinnati Children's Hospital Medical Center (CCHMC) parameters with modifications. Gray and white matter contacts will be stimulated systematically. Safety, tolerability, yield, validity and parameter space will be examined.
The invention relates to a medicine for treating reflux esophagitis. The medicine is prepared from, by weight, 15 parts of chlorite schist, 12 parts of Ixeris denticulate, 15 parts of medicated Leaven, 11 parts of blumea balsamifera, 7 parts of fruit shells or fruit of Quercus variabilis Bl., 6 parts of all grass or roots of Radix et Herba Lysimachiae Insignis and 10 parts of fruit of Amomum villosum Lour. Chlorite schist is used for making phlegm fall and helping digestion, and descending qi and calming livers. Ixeris denticulate is used for clearing away heat and toxic materials, draining pus and dissolving carbuncle, and activating blood circulation and eliminating stagnation. Medicated Leaven is used for invigorating spleens to promote digestion, regulating qi and eliminating dampness, and relieving exterior syndromes. Blumea balsamifera is used for dispelling wind and eliminating dampness, warming the middle and stopping diarrhoea, and activating blood and clearing away toxin. Fruit shells or fruit of Quercus variabilis Bl. are used for stopping coughs and diarrhoea, stopping bleeding and clearing away toxin. All grass or roots of Radix et Herba Lysimachiae Insignis are used for dispelling wind and removing obstruction in meridians, and promoting qi to activate blood. Fruit of Amomum villosum Lour. Chlorite schist is used for loosening chests, regulating qi, regulating essence and harmonizing stomachs. All the medicines are used in cooperation for achieving the functions of removing heat from livers, releasing heat, dispersing blood stasis, calming adverse-rising energy, guiding qi downwards and preventing or arresting vomiting. It is proved through clinical experiments that the medicine can safely and effectively treat reflux esophagitis.
The Arrow PICC with Arrowga+rd Blue Advanced protection (Teleflex Medical Incorporated, Morrisville, NC, USA; hereafter referred to as "AGBA") is an FDA-cleared pressure injectable device that offers both antimicrobial and anti-thrombogenic protection for at least 30 days. The application of Arrowga+rd Blue Advanced protection uses a proprietary process whereby chlorhexidine is chemically bonded to the intra- luminal catheter surfaces from tip to hub, and extra-luminal catheter body. The device is cleared for marketing in the United States of America by the Food and Drug Administration, and has obtained the CE mark for marketing in the European Union. The French size and length selected for use will be documented.